Skip to content
AnalystLens

Omega Healthcare Investors 8-K Report, Corporate Update (Sep 6, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed September 6, 2024
Period End
September 6, 2024
Security
OHI
In the record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed September 6, 2024. Cited figures are marked; the original filing is the authoritative source.

On September 6, 2024, Omega Healthcare Investors, Inc. entered into a new at-the-market equity offering sales agreement with a group of Sales Agents, Forward Sellers and Forward Purchasers, under which it may sell common stock (par value $0.10a per share) with an aggregate gross sales price not to exceed $1,250,000,000.

On the same date, the company terminated its prior at-the-market sales agreement dated May 20, 2021. The Securities will be offered under an automatic shelf registration statement on Form S-3 (No. 333-277916) and a prospectus supplement dated September 6, 2024. The company may sell Issuance Shares through the Sales Agents, either as agents or directly to them as principals, and may enter into forward sale agreements in which Forward Purchasers borrow and sell shares through Forward Sellers.

Sales are made at prevailing market prices on the New York Stock Exchange or as otherwise permitted, and the company has no obligation to sell any securities and may suspend offers at any time. Sales Agents may receive compensation of up to 2.0%b of the gross sales price of shares sold through them, and Forward Sellers may receive commissions of up to 2.0% in the form of a reduced initial forward sale price. The company expects to physically settle forward sale agreements by delivering shares and receiving proceeds on settlement dates no later than two years from entry into each agreement, but it may elect cash or net share settlement, in which case it may receive no proceeds and may owe cash or shares to the Forward Purchaser.

The filing also notes that several Sales Agents and their affiliates have had and may have other commercial banking and investment banking relationships with the company and its subsidiaries. Exhibits include the sales agreement, a legal opinion from Shapiro Sher Guinot & Sandler, P.A., and a tax opinion from Bryan Cave Leighton Paisner LLP.

Key Highlights

  1. New at-the-market equity program with aggregate gross sales price capped at $1.25 billion, replacing the prior sales agreement dated May 20, 2021, which was terminated on September 6, 2024.
  2. Shares may be sold through a broad group of 22 Sales Agents or via forward sale agreements with Forward Purchasers, at prevailing market prices on the New York Stock Exchange or at negotiated prices.
  3. Sales Agent compensation is capped at 2.0% of gross sales price, and Forward Seller commissions are capped at 2.0%, paid through a reduced initial forward sale price.
  4. The company has no obligation to sell any securities and may suspend offerings at any time.
  5. Forward sale agreements are expected to settle physically within two years, but the company may elect cash or net share settlement, which could mean receiving no proceeds.
  6. Offering is made under automatic shelf registration statement on Form S-3 (No. 333-277916) with a prospectus supplement dated September 6, 2024.
  7. Signed by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary.

Frequently Asked Questions

  1. How much equity can Omega Healthcare Investors sell under this new program?

    The Securities sold under the Sales Agreement may not exceed an aggregate gross sales price of $1,250,000,000 (i.e., $1.25 billion).

  2. What happened to the company's prior at-the-market program?

    On September 6, 2024, the company terminated its prior at-the-market equity offering sales agreement dated May 20, 2021.

  3. Is the company required to sell shares under this program?

    No. The company has no obligation to sell any of the Securities under the Sales Agreement and may at any time suspend solicitation and offers.

  4. What fees apply to sales under the program?

    Each Sales Agent is entitled to compensation not exceeding 2.0% of the gross sales price of Issuance Shares sold through it. Forward Sellers are entitled to commissions at a mutually agreed rate not exceeding 2.0% of the gross sales price of borrowed shares sold, paid as a reduced initial forward sale price.

  5. How could forward sale agreements affect the company's proceeds?

    The company expects to physically settle forward sale agreements and receive proceeds no later than two years after entry. However, it may elect cash settlement, in which case it may receive no proceeds and may owe cash to the Forward Purchaser, or net share settlement, in which case it will receive no proceeds and may owe shares to the Forward Purchaser.